HIV

Tenofovir Use Safe During Pregnancy

Tenofovir Use Safe During Pregnancy

By

Further research on longer-term effects of maternal prenatal TDF use is important given the majority of HIV-infected women are prescribed a TDF-containing prevention of mother-to-child transmission regimen.

Dual Regimen Provides Simple and Safe Salvage Therapy in HIV-1

Dual Regimen Provides Simple and Safe Salvage Therapy in HIV-1

By

Switching to dolutegravir plus darunavir/ritonavir provided a simple and safe rescue regimen, controlling viral replication in a high proportion of patients.

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

By

Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.

Carotid Plaque, Risk of Vascular Disease Events Higher in HIV

Carotid Plaque, Risk of Vascular Disease Events Higher in HIV

By

Findings show that HIV status was associated with an increased rate of incidental carotid plaque, noncalcified plaque, and high-risk plaque.

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

By

Daily cannabis use remained significantly associated with lower odds of steatosis even after adjustment for BMI, which is known to be inversely correlated with cannabis use.

Efficacy of Maraviroc-Containing HIV PrEP in Women Evaluated

Efficacy of Maraviroc-Containing HIV PrEP in Women Evaluated

Maraviroc (MVC)-containing HIV PrEP regimens are well tolerated for preventing HIV infection in uninfected women.

Adolescents at Risk for HIV Should Be Offered PrEP

Adolescents at Risk for HIV Should Be Offered PrEP

By

Experts discuss new findings supporting the need for PrEP in adolescents and discuss the continued debate surrounding parental consent and other relevant issues.

CDC Contraception Recommendations Updated for Women at Risk for HIV

CDC Contraception Recommendations Updated for Women at Risk for HIV

By

Women should not be denied the use of progestin-only injectables because of concerns about the possible increased risk of acquiring HIV.

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

By

Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.

Improving Linkage to Care in HIV Testing for Women

Improving Linkage to Care in HIV Testing for Women

Many women who are newly diagnosed with HIV have already been diagnosed but are not getting HIV medical care.

Pre-Exposure Prophylaxis Program for MSM Cost-Effective in UK

Pre-Exposure Prophylaxis Program for MSM Cost-Effective in UK

HIV PrEP in the UK for men who have sex with men might be cost-effective.

Safety, Efficacy of TAF vs TDF in HIV+ Adults Stratified by Race

Safety, Efficacy of TAF vs TDF in HIV+ Adults Stratified by Race

By

Among HIV-infected, virologically suppressed black adults, FTC/TAF showed improvements in renal and bone safety compared to FTC/TDF.

Frequent Syphilis Screening Necessary for High-Risk Populations

Frequent Syphilis Screening Necessary for High-Risk Populations

By

In 2004, syphilis screening guidelines were changed to recommend rapid plasma regain testing every 3 to 6 months.

FDA Approves Dose Modification for Children With HIV

FDA Approves Dose Modification for Children With HIV

By

The FDA has approved labeling changes for Genvoya to include new safety and efficacy data.

HIV Diagnosis Notification Rates Up Among Older Adults

HIV Diagnosis Notification Rates Up Among Older Adults

Notification rates of new HIV diagnoses in older adults increased in 16 European countries from 2004 to 2015.

Skin Diseases Remain Common in Older Adults With HIV

Skin Diseases Remain Common in Older Adults With HIV

By

Cutaneous manifestations are frequently associated with immune dysfunction in HIV.

Challenges in Multidrug-Resistant HIV Management: Ibalizumab Safe, Effective

Challenges in Multidrug-Resistant HIV Management: Ibalizumab Safe, Effective

By

Ibalizumab may be a valuable option in patients with multidrug-resistant HIV.

Examining Drug-Drug Interactions in Women With HIV: ART and Hormonal Contraception

Examining Drug-Drug Interactions in Women With HIV: ART and Hormonal Contraception

By

Examining the barriers to co-use of hormonal contraceptives and antiretroviral therapy in women with HIV.

Assessing the Risk Factors of Neurocognitive Decline in HIV+ Individuals

Assessing the Risk Factors of Neurocognitive Decline in HIV+ Individuals

By

The incidence of neurocognitive impairment is high in HIV-infected population, despite the introduction of combination antiretroviral therapy (CART).

New Antiretroviral Therapy Recommendations for Pregnant Women With HIV

New Antiretroviral Therapy Recommendations for Pregnant Women With HIV

By

The GRADE framework recommendations provide guidance for combination treatment regimens based on 2 systemic reviews, patient considerations, fetal outcomes, and practical issues.

Clinical Practice Guidelines Updated for Chronic Pain Management in HIV

Clinical Practice Guidelines Updated for Chronic Pain Management in HIV

By

The Infectious Diseases Society of America recommends that people living with HIV be screened for pain.

PrEP Adherence in Adolescent MSM Decreases Over Time

PrEP Adherence in Adolescent MSM Decreases Over Time

PrEP adherence decreases in adolescent MSM with quarterly visits during 48-week intervention.

Children With HIV Not Receiving Recommended Frequency of Medical Care

Children With HIV Not Receiving Recommended Frequency of Medical Care

A substantial proportion of children with diagnosed HIV infection might not be receiving the recommended frequency of medical care.

Abacavir ART Does Not Increase Risk for Myocardial Infarction or CVD

Abacavir ART Does Not Increase Risk for Myocardial Infarction or CVD

By

Abacavir-containing antiretroviral therapy does not appear to confer an increased risk for myocardial infarction or coronary artery disease.

Stroke Outcomes Similar in People With, Without HIV

Stroke Outcomes Similar in People With, Without HIV

By

Stroke outcomes between people with and without HIV were comparable.

Dyslipidemia in Children With HIV Started on Antiretroviral Therapy

Dyslipidemia in Children With HIV Started on Antiretroviral Therapy

By

Researchers aim to identify changes in blood lipid profiles among children with HIV after 12 months of using antiretroviral therapy.

EMERALD Trial: Week 48 Results Demonstrate Efficacy in Single-Tablet HIV Therapy

EMERALD Trial: Week 48 Results Demonstrate Efficacy in Single-Tablet HIV Therapy

By

Primary study end point was noninferiority of the single-tablet regimen vs control, related to virologic rebound, cumulative through week 48.

Do Traditional Risk Factors for CVD Play Larger Role in HIV-Positive Premenopausal Women?

Do Traditional Risk Factors for CVD Play Larger Role in HIV-Positive Premenopausal Women?

By

Traditional risk factors may incur a higher risk for CVD in HIV-positive premenopausal women than HIV infection itself.

Bictegravir Co-Formulation Maintained High Levels of Virologic Suppression in HIV

Bictegravir Co-Formulation Maintained High Levels of Virologic Suppression in HIV

By

Phase 3 study assessed efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide from a multi-tablet regimen containing a boosted protease inhibitor regimen in virologically suppressed patients with HIV.

Why Patients Discontinue ART— and What You Can Do to Stop It

Why Patients Discontinue ART— and What You Can Do to Stop It

By

Learn more about when stopping antiretroviral therapy (ART) may be necessary, why patients discontinue ART, predicting viral suppression, and predicting and encouraging adherence.

Sign Up for Free e-newsletters